Synapsoft logo
AI Insights from Disclosures
Searching...
Oncocross Co.,Ltd. 382150
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Oncocross Co.,Ltd. has focused on developing an AI platform to improve the efficiency of new drug development, based on the recognition that new drug development is stagnating due to the long time, enormous research costs, and associated risks required by traditional drug development methods. The company was the first in Korea to develop and operate RAPTOR AI, which uses AI to analyze changes in gene expression data (transcriptome) following drug administration or disease onset and matches diseases with optimal treatments, and its main business is to use this platform to screen for the optimal indications or combination drugs and to discover promising therapeutic drugs and targets for diseases.
Representative Director 김이랑, 강지훈 (각자대표)
Founded June 22, 2015
Corporation Type KOSDAQ
Industry Classification Research and experimental development on physics, chemistry and biology
Corporate number 11011-5758333
Business number 482-86-00109
Phone Number 02-867-9967
Fax Number 028679968
Company Address 7 Beobwon-ro 11-gil, Songpa-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant